According to Fintel, Wells Fargo has maintained its coverage of Cabaletta Bio (NASDAQ:CABA) with an Overweight recommendation.
Analysts have forecasted a 27.74% increase in the stock price of Cabaletta Bio, with an average one-year price target of $20.20, ranging from $14.14 to $35.70.
For Cabaletta Bio, the projected annual revenue is $0MM, and the projected annual non-GAAP EPS is -$1.53.
There are currently 173 funds or institutions reporting positions in Cabaletta Bio, which is a 49.14% increase compared to the previous quarter. The average portfolio weight of all funds dedicated to CABA is 0.27%, a decrease of 9.70%. Institutions now own a total of 41,404K shares, representing a 47.27% increase over the last three months. The put/call ratio of CABA is 0.45, indicating a bullish outlook.
Among the major shareholders, Fred Alger Management holds 4,573K shares, representing 11.49% ownership of the company. Adage Capital Partners Gp, L.l.c. holds 3,267K shares, representing 8.21% ownership. AOFAX – Alger Small Cap Focus Fund holds 3,059K shares, representing 7.68% ownership. Commodore Capital holds 2,368K shares, representing 5.95% ownership. Deerfield Management Company, L.p. holds 2,340K shares, representing 5.88% ownership.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company’s lead product candidate is being evaluated as a potential treatment for patients with mucosal pemphigus vulgaris, and their lead preclinical product candidate is being developed as a potential treatment for patients with MuSK-associated myasthenia gravis.
Fintel is a comprehensive investing research platform that offers data on fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, and more. Their exclusive stock picks are powered by advanced quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
